CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND: Single Audit Reports and Findings
CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND filed 5 single audits between 2016 and 2020; the most recently observed auditor is PRICEWATERHOUSECOOPERS LLP (2020), and the 2020 report lists 2 findings. Data as of 2026-09-18.
Data as of Sep 18, 2026 · Source: Federal Audit Clearinghouse (public data)
Single audits by year
One row per audit year as the Federal Audit Clearinghouse accepted it. The auditor named is the one observed on that filing; CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND is recorded in OAKLAND, California under EIN 940382330, and the Clearinghouse records it as a nonprofit.
| Audit year | Fiscal year end | Federal expended | Threshold applied | Auditor observed | Findings | MW / SD | FAC report |
|---|---|---|---|---|---|---|---|
| 2020 | 2020-06-30 | $9,260,375 | $750,000 | PRICEWATERHOUSECOOPERS LLP | 2 | — | 2020-06-CENSUS-0000117856 |
| 2019 | 2019-06-30 | $14,532,575 | $750,000 | PRICEWATERHOUSECOOPERS LLP | 1 | — | 2019-06-CENSUS-0000117856 |
| 2018 | 2018-06-30 | $17,143,466 | $750,000 | PRICEWATERHOUSECOOPERS LLP | 54 | — | 2018-06-CENSUS-0000117856 |
| 2017 | 2017-06-30 | $17,351,956 | $750,000 | PRICEWATERHOUSECOOPERS LLP | 382 | — | 2017-06-CENSUS-0000117856 |
| 2016 | 2016-06-30 | $20,705,467 | $750,000 | PRICEWATERHOUSECOOPERS LLP | 285 | — | 2016-06-CENSUS-0000117856 |
Which federal programs did this organization report?
From the most recent accepted report. "Major" is the designation the auditor made under 2 CFR 200.518, not ours.
| ALN | Program | Expended | Major |
|---|---|---|---|
| 93.224 | HEALTH CENTER PROGRAM | $1,334,511 | No |
| 93.110 | HEMOPHILIA TREATMENT CENTERS | $1,122,929 | No |
| 93.153 | RYAN WHITE TITLE IV WOMEN, INFANTS, CHILDREN, YOUTH AND AFFECTED FAMILY MEMBERS AIDS HEALTHCARE | $984,955 | Yes |
| 98.839 | SC-LINKS - LINKING THE SICKLE CELL COMMUNITY, PROVIDERS AND SYSTEMS TO IMPROVESICKLE CELL DISEASE CARE | $820,293 | Yes |
| 93.855 | MENINGOCOCCAL SEROGROUP B VACCINE TO PREVENT INVASIVE DISEASE AND CARRIAGE | $524,896 | Yes |
| 93.846 | THE PREGNANCY TRANSCRIPTOME IN RHEUMATOID ARTHRITIS | $498,909 | Yes |
| 93.847 | ENDOGENOUS AND DIETARY SPHINGOLIPIDS AS MODULATOR OF INFLAMMATORY BOWEL DISEASE | $486,727 | Yes |
| 93.855 | THE EFFECT OF BINDING OF FH TO MENINGOCOCCAL FHBP VACCINE ON ANTIBODY PROTECTION | $458,333 | Yes |
| 93.575 | CHILD ABUSE TREATMENT PROGRAM | $257,928 | No |
| 93.110 | THALASSEMIA | $245,262 | No |
| 93.297 | REPLICATION OF PROGRAMS PROVEN EFFECTIVE THROUGH RIGOROUS EVALUATION. TEEN PREGANCY PREVENTION | $244,580 | No |
| 16.243 | INFANCY AND EARLY CHILDHOOD MENTAL HEALTH CONSORTIUM: WORKFORCE DEVELOPMENT | $222,501 | No |
| 93.884 | PRIME CARE TRAINING AND ENHANCEMENT | $217,274 | No |
| 93.837 | THE ROLE OF PHOSPHATIDYLINOSITIDES IN LIPID METABOLISM | $207,607 | Yes |
| 93.855 | MENINGOCOCCAL AND GONOCOCCAL VACCINE TO PREVENT INVASIVE DISEASE AND CARRIAGE | $179,791 | Yes |
| 93.184 | CHARACTERIZING THE COMPLICATIONS ASSOCIATED WITH THERAPEUTIC BLOOD TRANSFUSIONS FOR HEMOGLOBINOPATHI | $170,801 | Yes |
| 93.914 | PART A OF THE RYAN WHITE HIV/AIDS TREATMENT MODERNIZATION ACT OF 2009 | $169,985 | No |
| 93.855 | IMPROVED PROTEIN-BASED MENINGOCOCCAL SEROGROUP B VACCINESMENINGOCOCCAL B VACCINES | $157,605 | Yes |
| 93.855 | CYTOMEGALOVIRUS TROPISMS FOR ORAL CELLS: KEY TO A VACCINE TO PREVENT MATERNALINFECTION | $148,175 | Yes |
| 93.837 | BAY AREA CHORI/UCSF SUMMER RESEARCH PROGRAM | $124,510 | Yes |
| 16.560 | DEVELOPMENT OF A PROBE CAPTURE NEXT-GENERATION SEQUENCING ASSAY FOR ANALYSIS OF THE MITOCHONDRIAL GENOME AND NUCLEAR MARKERS | $122,478 | Yes |
| 93.865 | VALIDATION DECISION RULES FOR CT USE IN CHILDREN WITH ABDOMINAL OR HEAD TRAUMA | $99,923 | Yes |
| 93.838 | CORE-ORBEX: PRIMARY PREVENTION OF ASTHMA AND WHEEZING IN CHILDREN | $98,511 | Yes |
| 93.855 | MULTIPLEX DIAGNOSTIC FOR BIOTHREAT C. PSITTACI & NON-THREAT RESPITORY PATHOGENS | $94,991 | Yes |
| 93.846 | A PRECISION MEDICINE APPROACH TO ASSESS PROGRESS FROM UNDIFFERENTIATED ARTHRITIS TO RHEUMATOID ARTHRITIS | $88,073 | Yes |
What findings did the auditor report?
The reference and the requirement letter are the ones the auditor used. The finding text itself is not reproduced here; the FAC report linked above carries it in full.
| Reference | Requirement | Severity | Repeat |
|---|---|---|---|
| 2020-002 | F | Other | No |
| 2020-003 | B | Questioned costs | No |
Form 990 and IRS registration
Form 990 "accounting fees" (Part IX line 11c) cover all accounting services reported by the organization and are not the price of an audit engagement.
- Total revenue
- $916,259,379
- Total assets
- $1,289,279,597
- IRS object id
- 202641359349311044
- NTEE code
- E240
- Exempt under
- 501(c)(3)
- Ruling year
- 1934
- BMF release
- 2026-09-17
Read next
- CPA firms that audit California nonprofits
- California single audit statistics
- California nonprofit audit requirements
How we computed this
Every row comes from the Federal Audit Clearinghouse record named beside it, one report per audit year, with a resubmission superseding the filing it replaces. The auditor is the one named on that filing — it is not a statement about who audits CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND now. Form 990 figures come from the IRS e-filed return named by its object id. This page exists because the organization filed at least two single audits, or one with a finding.
Cite this page
AuditRadar. “CHILDREN'S HOSPITAL & RESEARCH CENTER AT Single Audits.” https://getauditradar.com/single-audits/ca/children-s-hospital-and-research-center-at-oakland-940382330/. Data as of 2026-09-18.